Evaluation of the efficacy of silodosin 8 mg in comorbid patients with LUTS/BPH

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Introduction. According to domestic and foreign publications, benign prostatic hyperplasia (BPH) is one of the most common urological diseases among older men, which prevalence reaches 50% by the age of 60. Aim. To analyze the efficiency of the use of the alpha1-blocker silodosin at a dose of 8 mg a day in comorbid patients with lower urinary tract symptoms (LUTS), associated with BPH. Materials and methods. A total of 197 comorbid patients with LUTS/BPH were included in the study. All men underwent a standard examination. They were divided into 2 groups without differences in baseline parameters. In the main group (n=100) patients received silodosin at a dose of 8 mg, while in the control group 97 men did not receive any drug therapy for LUTS. Discussion. There were significant differences between groups in the total IPSS score, postvoid residual (ml), maximum urine flow rate (ml/s), patient satisfaction with treatment efficacy based on the TS-VAS visual analogue scale (total score). However, we didn’t find significant differences in rate of cardiovascular side effects between the groups. Conclusions. Treatment of comorbid patients with LUTS/BPH with silodosin at a dose of 8 mg results in significant improvement and is not associated with cardiovascular adverse events.

Full Text

Restricted Access

About the authors

A. A Zimichev

FGBOU VO Samara State Medical University

Email: zimichew@mail.ru
Ph.D., MD, professor at the Department of Urology Samara, Russia

D. O Gusev

REAVIZ Medical University

Assistant of the Department of Surgical Diseases No. 2 Samara, Russia

D. Yu Lukyanova

REAVIZ Medical University

Assistant of the Department of Internal Diseases Samara, Russia


  1. Enikeev D., Glybochko P., Alyaev Y., et al. Retrospective analysis of short-term outcomes after monopolar versus laser endoscopic enucleation of the prostate: a single center experience. Journal of Endourology. 2018;325(5):417-423.
  2. Enikeev D.V., Glybochko P.V., Alyaev Y.G., et al. Endoscopic prostate enucleation is a new standard of surgical treatment of prostatic hyperplasia. Andrologiya i genitalnaya xirurgiya. 2017;18(3):83-88.
  3. Oganov R.G., Simanenkov V.l., Bakulin I.G. et al. Clinical guidelines. Cardiovascular therapy and prevention. 2019;18(1):5-66. http://dx.doi.org/10.15829/1728-8800-2019-1-5-66
  4. Burke A.P., Farb A, Malcolm G.T. et al. Coronary risk factors and plaque morfology in men with coronary death who died suddenly. N Engl J Med. 1997;336:1276-1281.
  5. Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A.Comparative analysis of the effectiveness of early and delayed initiation of combined drug therapy of BPH. Urologiia. 2021;2:27-31.
  6. European Association of Urology Guidelines on Urological Infections. URL: www.uroweb.org
  7. Pool J.L. Alpha receptors in hypertension (HTN) and benign prostatic hyperplasia (BPH). American Journal of Hypertension. 1995;8(994):9A.
  8. Owens G.M. Successful aging in men with BPH. American Journal of Managed Care. 2006;12(Suppl. 5).
  9. Alyaev Y.G., Akopyan G.N., Ali S.X. et al. From symptoms to diagnosis and treatment. Illustrated guide. Uchebnoe posobie. Moskva, 2021. (2-e izdanie).
  10. Enikeev D., Sukhanov R., Chinenov D. et al. EAU, AUA and NICE guidelines on surgical and minimally invasive treatment of benign prostate hyperplasia: a critical appraisal of the guidelines using the AGREE-II tool. Urologia Internationalis. 2021.
  11. Rees J., Foley S., Huang M., Arias J.R., Skoumal R., Walters C., Yavuz Y., De Wachter S. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Experimental & Clinical Urology. 2019;3:134-143.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies